What’s the current market cap for Centene stock?

Centene (CNC) has a market cap of $31bn as of June 24, 2026.

What is the P/E ratio for Centene stock?

The price to earnings (P/E) ratio for Centene (CNC) stock is 0 as of June 24, 2026.

Does Centene stock pay dividends?

No, Centene (CNC) stock does not pay dividends to its shareholders as of June 24, 2026.

When is the next Centene dividend payment date?

Centene (CNC) stock does not pay dividends to its shareholders.

What is the beta indicator for Centene?

Centene (CNC) has a beta rating of 1.06. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Centene stock | $CNC Share Price

13:30

09:10

04:45

00:25

20:00

About Centene

Centene is a managed care organization that focuses on government-sponsored healthcare plans, including Medicaid, Medicare, and the individual exchanges. Centene served 20 million medical members as of December 2025, mostly in Medicaid (about 64% of membership), the individual exchanges (about 28%), and Medicare (about 5%). The company also provides Medicare Part D pharmaceutical plans.

Ticker

$CNC

Sector

Health

Primary listing

NYSE

Employees

61,100

Headquarters

Saint Louis, United States

Website

www.centene.com

Centene Metrics

BasicAdvanced

$31bn

-$13.10

1.06

What the Analysts think about Centene

Analyst ratings (Buy, Hold, Sell) for Centene stock.

Bulls say / Bears say

Centene reported 7.1% growth in first-quarter 2026 revenue to $49.94 billion and delivered adjusted EPS of $3.37, beating analyst estimates by about 58%, demonstrating its scale and operational efficiency. (Reuters)

On April 28, Centene raised its 2026 adjusted profit guidance after lowering its medical loss ratio to 87.3% in Q1 through disciplined cost controls, showing strong expense management. (Reuters)

On February 6, Centene updated its 2026 full-year adjusted EPS guidance to above $3 per share, surpassing Bloomberg’s $2.88 consensus, reflecting management’s confidence in margin recovery efforts. (Bloomberg)

Obamacare plan enrollment dropped by over one million to around 23 million for 2026 as federal subsidies ended, putting pressure on Centene’s Marketplace membership and revenue outlook. (Reuters)

A draft proposal for a 0.09% increase in 2027 Medicare Advantage payment rates sent Centene shares down 11%, indicating likely margin reduction and potential cuts to benefits in its main Medicare Advantage business. (Reuters)

On April 3, S&P Global downgraded Centene’s long-term issuer credit rating to BB+ from BBB−, citing concerns about leverage and execution risks in a volatile policy environment. (S&P Global)

Data summarised monthly by Lightyear AI. Last updated on 30 May 2026.

Centene Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

Centene Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Bulls say / Bears say

On April 28, Centene raised its 2026 adjusted profit guidance after lowering its medical loss ratio to 87.3% in Q1 through disciplined cost controls, showing strong expense management. (Reuters)

Obamacare plan enrollment dropped by over one million to around 23 million for 2026 as federal subsidies ended, putting pressure on Centene’s Marketplace membership and revenue outlook. (Reuters)

On April 3, S&P Global downgraded Centene’s long-term issuer credit rating to BB+ from BBB−, citing concerns about leverage and execution risks in a volatile policy environment. (S&P Global)

Data summarised monthly by Lightyear AI. Last updated on 30 May 2026.